Stefano Rocco

Stefano Rocco

Auto-generated profile, based on publicly available information

Stefano Rocco

Division of Hematology, AO “A. Cardarelli’’ Hospital, Naples, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2017 in Geophysical Research Letters
Verified
Journal Article
Open access
PDF file
SRStefano Rocco
Stefano Rocco
AWAndrew W. Woods
Andrew W. Woods
JHJon Harrington
Jon Harrington
SNSimon Norris
Simon Norris
We present new experiments that identify a mechanism for episodic release of gas from a pressurized, deformable reservoir confined by a clay seal, as a result of the transition from bulk deformation to channel growth through the clay. Air is injected into the center of a thin cylindrical cell initially filled with a mixture of bentonite clay and water. For sufficiently dry mixtures, the pressure initially increases with little volume change. On reaching the yield stress of the clay‐water mixture, the lid of the cell then deforms elastically and an air‐filled void forms in the center of the cell as the clay is driven radially outward. With continued supply of air, the pressure continues to increase until reaching the fracture strength of the clay. A fracture‐like channel then forms and migrates to the outer edge of the cell, enabling the air to escape. The pressure then falls, and the clay flows back toward the center of the cell and seals the channel so the cycle can repeat. The phenomena may be relevant at mud volcanoes.

5 September 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
RPRoberta Della Pepa
Roberta Della Pepa
SPSalvatore Palmieri
Salvatore Palmieri
SRStefano Rocco
Stefano Rocco
NPNovella Pugliese
Novella Pugliese
ALAldo Leone
Aldo Leone
FPFabrizio Pane
Fabrizio Pane
Daratumumab combined with bortezomib, thalidomide, and dexamethasone (Dara-VTD) is a highly effective induction therapy for newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplantation (ASCT). However, its impact on stem cell mobilization requires a critical evaluation. This study examines the effects of Dara-VTD on stem cell mobilization and collection outcomes. A multicenter retrospective study included 81 consecutive NDMM patients treated with Dara-VTD (from November 2021 to June 2023). Data on stem cell mobilization and collection were compared with 93 historical VTD patients. Mobilization regimens included cyclophosphamide (CTX), vinorelbine + CTX, and chemotherapy-free approaches, with plerixafor used as rescue therapy. Mobilization success was evaluated by CD34 + cell yield, additional agent use, and leukapheresis sessions required. The median CD34 + yield in the Dara-VTD group was 5.1 million cells/kg, with 96.3% of patients achieving > 2 × 10^6 cells/kg of body weight. Plerixafor use was significantly higher in the Dara-VTD group (56.2%) compared to VTD (4.3%), and CTX-based regimens showed superior mobilization efficacy ( p = 0.01). Engraftment was faster in the Dara-VTD group, with median neutrophil and platelet recovery at 11 and 13 days, compared to 12 and 17 days in the VTD group ( p < 0.05). Dara-VTD maintains the feasibility of ASCT, with comparable stem cell mobilization and collection outcomes to VTD. Mobilization success is influenced by individualized strategies, with CTX and plerixafor playing key roles in optimizing stem cell yield. Despite the challenges posed by daratumumab, stem cell mobilization remains effective, and Dara-VTD does not compromise the transplant process.